• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The considerable mortality and morbidity associated with atrial fibrillation (AF) pose a
substantial burden on patients and health care services. Although the management of AF …

Background: In patients with heart failure and atrial fibrillation (AF), several clinical trials
have reported improved outcomes, including freedom from AF recurrence, quality of life, and …

Obesity is a growing health problem worldwide. It is associated with an increased
cardiovascular risk on the one hand of obesity itself and on the other hand of associated …

AFL atrial flutter AH arterial hypertension ANS autonomic nervous system APD action
potential duration ARREST-AF Aggressive Risk Factor Reduction Study for Atrial Fibrillation …

The Japanese Circulation Society (JCS) published the “Guidelines for Pharmacological
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …

The atria provide an important contribution to cardiac function. 1, 2 Besides their impact on
ventricular filling, they serve as a volume reservoir, host pacemaker cells and important parts …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

The recommendations listed in this guideline are, whenever possible, evidence based. An
extensive evidence review was conducted in April 2014 that included literature published …

Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by pathogenic
variants in the α‐galactosidase A (GLA) gene that leads to reduced or undetectable α …